The DOI matches its Crossref record.
[18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma
Open accessAbstract
BACKGROUND: To assess the sensitivity and specificity of [(18)F]-fluoro-ethyl-l-tyrosine ((18)F-FET) PET in brain tumors and various non-neoplastic neurologic diseases. METHODS: We retrospectively evaluated (18)F-FET PET scans from 393 patients grouped into 6 disease categories according to histology (n = 299) or distinct MRI findings (n = 94) (low-grade/high-grade glial/nonglial brain tumors, inflammatory lesions, and other lesions). (18)F-FET PET was visually assessed as positive or negative. Maximum lesion-to-brain ratios (LBRs) were calculated and compared with MRI contrast enhancement (CE), which was graded visually on a 3-point scale (no/moderate/intense). RESULTS: Sensitivity and specificity for the detection of brain tumor were 87% and 68%, respectively. Significant differences in LBRs were detected between high-grade brain tumors (LBR, 2.04 ± 0.72) and low-grade brain tumors (LBR, 1.52 ± 0.70; P < .001), as well as among inflammatory (LBR, 1.66 ± 0.33; P = .056) and other brain lesions (LBR, 1.10 ± 0.37; P < .001). Gliomas (n = 236) showed (18)F-FET uptake in 80% of World Health Organization (WHO) grade I, 79% of grade II, 92% of grade III, and 100% of grade IV tumors. Low-grade oligodendrogliomas, WHO grade II, had significantly higher (18)F-FET uptakes than astrocytomas grades II and III (P = .018 and P = .015, respectively). (18)F-FET uptake showed a strong association with CE on MRI (P < .001) and was also positive in 52% of 157 nonglial brain tumors and nonneoplastic brain lesions. CONCLUSIONS: (18)F-FET PET has a high sensitivity for the detection of high-grade brain tumors. Its specificity, however, is limited by passive tracer influx through a disrupted blood-brain barrier and (18)F-FET uptake in nonneoplastic brain lesions. Gliomas show specific tracer uptake in the absence of CE on MRI, which most likely reflects biologically active tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ahluwalia, M. S., Nayak, L., Peters, S., Arvold, N. D., Harsh, G. R., Steeg, P. S., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0055-y · Cited by 1,034
Albert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C., Pope, W., Law, I., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 744
Self-citationPrimary brain tumours in adults
van den Bent, M. J., Geurts, M., French, P. J., Smits, M., Capper, D., Bromberg, J. E. C., & Chang, S. M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01054-1 · Cited by 419
Advances in neuro-oncology imaging
Langen, K.-J., Galldiks, N., Hattingen, E., & Shah, N. J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.44 · Cited by 339
Raimondi, V., Toscani, D., Marchica, V., Burroughs-Garcia, J., Storti, P., & Giuliani, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015402 · Cited by 10
Metadata
- Authors
- Hutterer, M., Nowosielski, M., Putzer, D., Jansen, N. L., Seiz, M., Schocke, M., McCoy, M., Göbel, G., la Fougère, C., Virgolini, I. J., Trinka, E., Jacobs, A. H., & Stockhammer, G.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-17
- Volume
- 15
- Issue
- 3
- Pages
- 341-351
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2151540244
- Cited by
- 239
- References
- 0
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: [18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. https://app.cochat.ai/papers/10.1093/neuonc/nos300
- The paper
- Hutterer, M., Nowosielski, M., Putzer, D., Jansen, N. L., Seiz, M., Schocke, M., McCoy, M., Göbel, G., la Fougère, C., Virgolini, I. J., Trinka, E., Jacobs, A. H., & Stockhammer, G. (2013). [18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncology. https://doi.org/10.1093/neuonc/nos300
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.